{"id":7207,"date":"2022-06-03T12:11:40","date_gmt":"2022-06-03T10:11:40","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/06\/maat-pharma-ENG-02-06.pdf"},"modified":"2022-06-03T12:11:40","modified_gmt":"2022-06-03T10:11:40","slug":"maat-pharma-eng-02-06","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/maat-pharma-confirms-positive-results-from-completed-phase-1b-cimon-study-evaluating-maat033-in-blood-cancer-patients\/maat-pharma-eng-02-06\/","title":{"rendered":"maat pharma ENG 02 06"},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-7207","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"\n